US Stock MarketDetailed Quotes
INAB In8bio
- 0.286
- +0.006+2.21%
Close Nov 1 16:00 ET
- 0.284
- -0.002-0.84%
Post 20:02 ET
20.78MMarket Cap-349P/E (TTM)
0.295High0.272Low208.49KVolume0.280Open0.280Pre Close58.69KTurnover0.40%Turnover RatioLossP/E (Static)72.55MShares2.48052wk High1.52P/B14.80MFloat Cap0.21752wk Low--Dividend TTM51.68MShs Float10.319Historical High--Div YieldTTM8.14%Amplitude0.217Historical Low0.281Avg Price1Lot Size
About In8bio Company
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Company Profile
SymbolINAB
Company NameIn8bio
Listing DateJul 30, 2021
Issue Price10.00
Founded2016
CEOMr. William Ho
MarketNASDAQ
Employees31
Fiscal Year Ends12-31
Address350 5th Avenue,Suite 5330
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10118
Phone1-646-600-6438
Websitehttp://www.in8bio.com
Company Executives
- Name
- Position
- Salary
- William Ho
- Director, President and Chief Executive Officer
- 1.85M
- Patrick McCall
- Principal Accounting Officer, Chief Financial Officer and Secretary
- 914.84K
- Dr. Kate Rochlin, PhD
- Chief Operating Officer
- --
- Dr. Lawrence Lamb, PhD
- Executive Vice President and Chief Scientific Officer
- --
- Alan S. Roemer
- Chairman of the Board
- 256.42K
- Dr. Jeremy Graff, PhD
- Director
- 211.18K
- Dr. Corinne Epperly, PhD
- Director
- 48.87K
- Luba Greenwood
- Independent Director
- 181.42K
- Emily Wang Fairbairn
- Independent Director
- 172.92K
- Travis Whitfill
- Independent Director
- 163.67K
- Peter C. Brandt
- Independent Director
- 195.42K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data